GABRA6 Gene

📖 Wiki Page

gene2553 wordssynced 2026-04-02

GABRA6 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">gabra6</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GABRA6</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Gamma-Aminobutyric Acid Type A Receptor Alpha 6 Subunit</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>5q34</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>2565</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>137143</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000145945</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P47870</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>456 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~51 kDa</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Epilepsy, Cerebellar Ataxia, Alzheimer's Disease, Parkinson's Disease, Autism Spectrum Disorders</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cerebellar Cortex (Granule Cell Layer)</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">Cochlear Nuclei</td>
<td>High</td>
</tr>
<tr>
<td class="label">Thalamus (specific nuclei)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Olfactory Bulb</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Brainstem (cochlear and vestibular nuclei)</td>
<td>Moderate</td>

...

GABRA6 Gene

Introduction

The GABRA6 gene (Gamma-Aminobutyric Acid Type A Receptor Alpha 6 Subunit) encodes the alpha6 subunit of the GABA-A receptor, a critical inhibitory neurotransmitter receptor in the central nervous system. The alpha6 subunit is predominantly expressed in cerebellar granule cells, making it one of the most cell-type-specific GABA-A receptor subunits in the brain. This distinctive expression pattern has made GABRA6 an important model for understanding subunit-specific receptor function and cerebellar physiology. The gene has been implicated in various neurological conditions including epilepsy, cerebellar ataxias, Alzheimer's disease, and Parkinson's disease, as well as in neurodevelopmental disorders and psychiatric conditions.

The GABRA6 gene is located on chromosome 5q34 and encodes a protein that assembles with other GABA-A receptor subunits to form functional chloride channels. The alpha6 subunit-containing receptors are distinguished by their pharmacological properties, including specific sensitivity to certain modulators and their predominant localization to extrasynaptic sites. Research on GABRA6 has provided critical insights into the organization of cerebellar inhibitory circuits and the mechanisms by which genetic variations contribute to neurological disease.

Overview

Mermaid diagram (expand to render)

Gene Structure and Function

Protein Structure

The GABRA6 gene encodes the alpha6 subunit of the GABA-A receptor, a member of the Cys-loop family of ligand-gated ion channels. Like other GABA-A receptor subunits, the alpha6 protein contains several structural domains essential for receptor function:

N-terminal extracellular domain: Contains the characteristic Cys-loop motif (13 amino acids with a disulfide bond) that is shared across all Cys-loop receptors. This domain harbors the GABA binding site at the interface with beta subunits.
Transmembrane domains (M1-M4): Four alpha-helical transmembrane segments that form the ion channel pore. The M2 segment lines the channel pore and determines ion selectivity.
Intracellular loop: The intracellular loop between M3 and M4 is the largest domain and contains multiple sites for post-translational modifications including phosphorylation.
C-terminal extracellular domain: Contributes to subunit assembly and the formation of the extracellular ligand-binding domain.

The alpha6 subunit has several unique structural features that distinguish it from other alpha subunits:

Exon structure: The GABRA6 gene has a distinctive exon-intron organization that is subject to alternative splicing
Phosphorylation sites: Multiple serine and threonine residues in the M3-M4 loop serve as phosphorylation sites
Glycosylation sites: The extracellular domains contain N-linked glycosylation sites that affect folding and trafficking

Receptor Assembly

GABRA6-encoded alpha6 subunits assemble with other GABA-A receptor subunits to form functional pentameric receptors. The most common configurations include:

Alpha6-beta2-delta: The predominant extrasynaptic receptor configuration in cerebellar granule cells
Alpha6-beta3-gamma: Synaptic and perisynaptic receptors
Alpha6-alpha4-beta2: Mixed-subunit receptors occasionally observed

The assembly process is highly regulated:

ER quality control: Molecular chaperones in the endoplasmic reticulum ensure proper folding and assembly

Trafficking through Golgi: Properly assembled receptors are transported through the Golgi apparatus

Membrane insertion: Final insertion into the plasma membrane occurs with specific subcellular targeting

Normal Physiological Function

The GABA-A alpha6 subunit-containing receptors serve several critical physiological functions:

Cerebellar Inhibition: Alpha6-containing receptors are the predominant GABA-A receptor subtype in cerebellar granule cells, the most numerous neurons in the brain. These receptors provide inhibitory input to granule cells from Golgi cells in the cerebellar cortex, forming part of the inhibitory microcircuit that processes sensory information and coordinates motor learning.

Tonic Inhibition: Due to their extrasynaptic localization and high affinity for GABA, alpha6-containing receptors mediate tonic inhibition in cerebellar granule cells. This sustained inhibitory current sets the resting membrane potential and regulates neuronal excitability, influencing signal processing in cerebellar circuits.

Motor Coordination: Cerebellar granule cells process sensory information from mossy fibers and provide output to Purkinje cells via parallel fibers. Alpha6-containing receptors modulate this processing, contributing to motor coordination, balance, and procedural learning.

Temporal Processing: The fast kinetics of GABAergic inhibition through alpha6-containing receptors make them well-suited for temporal processing in cerebellar circuits. This is particularly important for the precise timing required in motor coordination and possibly in cognitive functions.

Auditory Processing: Alpha6-containing receptors are expressed in the cochlear nuclei, where they contribute to auditory signal processing. This reflects the broader role of cerebellar circuits in timing and sensorimotor integration.

Expression Pattern

GABRA6 exhibits a highly specific expression pattern:

This highly restricted expression makes GABRA6 one of the most cell-type-specific GABA-A receptor subunits, providing a molecular marker for cerebellar granule cells and related neuron populations.[@x2025]

Disease Associations

Cerebellar Ataxias

GABRA6 has been directly implicated in cerebellar ataxia syndromes:

Spinocerebellar Ataxia: Mutations in GABRA6 have been identified in patients with spinocerebellar ataxia type 19 (SCA19[@m2021]), a hereditary ataxia characterized by progressive cerebellar dysfunction. These mutations affect receptor function and trafficking, leading to impaired inhibitory signaling in cerebellar circuits.

Congenital Ataxia: Rare de novo variants in GABRA6 have been associated with congenital cerebellar ataxia, presenting in early childhood with motor delays and coordination deficits.

Mechanism: Loss of alpha6-containing receptor function leads to disinhibition of cerebellar granule cells, disrupting the precise inhibitory microcircuits required for proper motor coordination.

Epilepsy

GABRA6 is strongly implicated in epilepsy:

Genetic Epilepsy: Rare variants in GABRA6 have been identified in patients with genetic epilepsy syndromes, including childhood absence epilepsy and Lennox-Gastaut syndrome. These variants may alter receptor function or trafficking, contributing to network hyperexcitability.

Cerebellar Hyperexcitability: The cerebellum has emerged as an important contributor to seizure generation and propagation. Alpha6-containing receptors in the cerebellum modulate cerebellar output to thalamocortical circuits, and dysfunction may contribute to seizure susceptibility.

Anti-seizure Drug Targets: Several anti-seizure medications act on GABA-A receptors, including those containing the alpha6 subunit. The efficacy of drugs like topiramate and benzodiazepines may involve modulation of alpha6-containing receptors.

Alzheimer's Disease

GABRA6 and cerebellar GABAergic signaling are relevant to Alzheimer's disease:

Cerebellar Pathology: While traditionally considered relatively spared in AD, the cerebellum shows significant GABAergic dysfunction in Alzheimer's disease, including changes in alpha6-containing receptors.

Network Dysfunction: Cerebellar output influences cortical networks through thalamocortical pathways. Cerebellar inhibitory dysfunction may contribute to the network hyperexcitability and cognitive deficits observed in AD.

Theta Rhythm: The cerebellum contributes to theta rhythm generation important for memory processes. Alterations in alpha6-containing receptor function may disrupt these rhythms.

Parkinson's Disease

GABRA6 has implications for Parkinson's disease:

Cerebellar Involvement: The cerebellum is increasingly recognized as contributing to motor dysfunction in PD. Cerebellar granule cells and their inhibitory circuits, including alpha6-containing receptors, may be affected.

Motor Learning Deficits: Procedural learning deficits in PD involve cerebellar circuits. Alpha6-containing receptors modulate cerebellar plasticity and learning.

Non-motor Symptoms: Cerebellar involvement in non-motor symptoms of PD, including cognitive and mood disorders, may involve GABAergic dysfunction.

Therapeutic Implications: Cerebellar GABAergic modulation is being explored as a therapeutic target in PD, with alpha6-containing receptors as potential targets.

Autism Spectrum Disorders

GABRA6 may be relevant to autism:

Genetic Variants: Rare variants in GABRA6 have been identified in some individuals with ASD, though a direct causal relationship has not been established.

Cerebellar Dysfunction: Cerebellar abnormalities are among the most consistently reported neuroanatomical findings in ASD. Alpha6-containing receptors, as the predominant receptor in cerebellar granule cells, may contribute to cerebellar dysfunction in ASD.

Timing and Sensory Processing: The cerebellum's role in timing and sensory processing, functions that are often impaired in ASD, involves alpha6-containing receptors.

Schizophrenia

GABRA6 may have relevance to schizophrenia:

Expression Changes: Altered GABRA6 expression has been reported in postmortem brain tissue from schizophrenia patients.

Cognitive Deficits: The cerebellum's contribution to cognitive function, including working memory and executive processes, may involve alpha6-containing receptors.

Treatment Response: Cerebellar dysfunction may contribute to the cognitive deficits that persist despite antipsychotic treatment.

Molecular Mechanisms

Receptor Function

Alpha6-containing GABA-A receptors mediate inhibitory neurotransmission through a well-characterized mechanism:

GABA binding: GABA binds to the extracellular interface between alpha and beta subunits

Conformational change: Binding triggers a conformational change that opens the central chloride channel

Chloride flux: Chloride ions flow down their electrochemical gradient, hyperpolarizing the neuron

Inhibition: Reduced neuronal excitability and decreased action potential generation

The alpha6 subunit confers distinct properties:

High affinity for GABA: Alpha6-containing receptors have higher GABA affinity than many other subunit combinations
Slow desensitization: Relatively slow channel desensitization prolongs inhibitory currents
Distinct pharmacology: Unique sensitivity to certain modulators including neurosteroids and some insecticides

Regulation of Expression

GABRA4 expression is tightly regulated:

Cell-type specificity: The highly restricted expression of GABRA6 is controlled by transcriptional regulators that drive cell-type-specific expression in cerebellar granule cells.

Developmental regulation: GABRA6 expression increases during postnatal development, coinciding with the maturation of cerebellar circuits.

Activity-dependent regulation: Neuronal activity can modulate GABRA6 expression, allowing for adaptive changes in inhibitory signaling.

Post-translational Modifications

Several post-translational modifications regulate alpha6-containing receptor function:

Phosphorylation: PKC-mediated phosphorylation affects receptor trafficking and function
Glycosylation: N-linked glycosylation affects receptor assembly and cell surface expression
Palmitoylation: Regulates receptor localization and clustering at extrasynaptic sites

Therapeutic Targeting

Current Pharmacological Approaches

Drug Development

Cerebellar targeting: Developing compounds that specifically target cerebellar GABA-A receptors including alpha6-containing receptors.

Extrasynaptic selectivity: Creating compounds that preferentially enhance extrasynaptic inhibition through alpha6-delta-containing receptors.

Neurosteroid modulators: Developing neurosteroid-based compounds with selectivity for alpha6-containing receptors.

Animal Models

Knockout Models

GABRA6 knockout mice have provided important insights:

Motor coordination deficits: Knockout mice show impaired motor coordination on rotarod and other behavioral tasks
Altered cerebellar function: Electrophysiological studies reveal changes in cerebellar circuit function
Seizure susceptibility: Increased seizure susceptibility in some models

Transgenic Models

Transgenic and knock-in models have been used to study disease mechanisms:

Epilepsy models: Altered GABRA6 expression in genetic and acquired epilepsy models
Ataxia models: GABRA6 mutations cause ataxia in mouse models
PD models: Changes in cerebellar GABRA6 in parkinsonian models

Cross-Linking Connections

The GABRA6 gene page connects to multiple other wiki pages forming a comprehensive knowledge network:

[GABA-A Receptor](/proteins/gaba-a-receptor) - The complete receptor complex containing alpha6
[GABRB2](/genes/gabrb2) - Beta2 subunit that co-assembles with alpha6
[GABRD](/genes/gabrd) - Delta subunit, forms extrasynaptic receptors with alpha6
[GABRA4](/genes/gabra4) - Related alpha subunit

[GABA Signaling in Neurodegeneration](/mechanisms/gaba-imbalance)
[Cerebellar Circuitry](/mechanisms/cerebellar-circuitry)
[Tonic Inhibition](/mechanisms/tonic-inhibition)

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Epilepsy](/diseases/epilepsy)
[Spinocerebellar Ataxia](/diseases/spinocerebellar-ataxia)
[Autism Spectrum Disorders](/diseases/autism-spectrum-disorders)

Brain Regions

[Cerebellum](/brain-regions/cerebellum)
[Cochlear Nuclei](/brain-regions/cochlear-nuclei)
[Thalamus](/brain-regions/thalamus)

Research Directions

Current Research Focus

Active research areas include:

Cerebellar circuits: Understanding how alpha6-containing receptors contribute to cerebellar circuit function

Disease mechanisms: Defining how GABRA6 dysfunction contributes to ataxia, epilepsy, and other conditions

Therapeutic targeting: Developing subunit-selective compounds

Network contributions: Understanding cerebellar contributions to network dysfunction in neurodegenerative diseases

Knowledge Gaps

Areas requiring additional research include:

The specific role of cerebellar alpha6-containing receptors in different neurodegenerative diseases
Optimal strategies for targeting cerebellar inhibition therapeutically
Biomarkers for identifying patients who might benefit from alpha6-targeted therapies

Key Publications

[Farrant M, et al. (2005). Variations in GABA-A receptor alpha subunit expression: from physiology to pathophysiology. Nat Rev Neurosci.](https://pubmed.ncbi.nlm.nih.gov/15850925/)

[Mohler H, et al. (2007). GABA(A) receptor subtypes: function and pharmacology. Neuropharmacology.](https://pubmed.ncbi.nlm.nih.gov/17239925/)

[Rudolph U, et al. (2010). GABA(A) receptor subtypes: emerging functions. Neuropsychopharmacology.](https://pubmed.ncbi.nlm.nih.gov/19940842/)

[Luscher B, et al. (2011). GABA(A) receptor mutations in neurological disease. J Alzheimers Dis.](https://pubmed.ncbi.nlm.nih.gov/21248468/)

[Brickley SG, et al. (2012). Extrasynaptic GABA-A receptors as targets for antiepileptic drugs. J Physiol.](https://pubmed.ncbi.nlm.nih.gov/22473780/)

[Drawnel FM, et al. (2019). GABAergic signaling in the cerebellum and its dysfunction in neurological disorders. Cerebellum.](https://pubmed.ncbi.nlm.nih.gov/30828755/)

[Wallace MJ, et al. (2021). Cerebellar GABA-A receptor alpha6 subunit in health and disease. Neuropharmacology.](https://pubmed.ncbi.nlm.nih.gov/33486152/)

[Zhang Y, et al. (2022). Role of cerebellar GABAergic dysfunction in Alzheimer's disease. Front Cell Neurosci.](https://www.frontiersin.org/articles/10.3389/fncel.2022.817640/full)

Background

The study of GABRA6 has provided critical insights into cerebellar function and inhibitory neurotransmission. The highly restricted expression of GABRA6 in cerebellar granule cells has made it an important model for understanding cell-type-specific receptor function and the organization of cerebellar microcircuits.

Early research focused on characterizing the pharmacological properties of alpha6-containing receptors, revealing their unique sensitivity to various modulators and their predominant extrasynaptic localization. Subsequent work established the subunit's role in tonic inhibition and motor coordination, with knockout mice demonstrating clear motor coordination deficits.

More recent investigations have expanded understanding of GABRA6's involvement in disease processes. The identification of GABRA6 mutations in patients with cerebellar ataxia and epilepsy has motivated studies of the molecular mechanisms by which these variants influence receptor function. At the same time, the recognition that cerebellar dysfunction contributes to neurodegenerative diseases including AD and PD has sparked interest in understanding how alpha6-containing receptors might be targeted therapeutically.

The cerebellum's emerging role in non-motor functions, including cognition and emotion, has also motivated investigation of how alpha6-containing receptors might contribute to these processes. This work is ongoing, with several research groups exploring the cerebellar contributions to neuropsychiatric disorders and the potential for cerebellar-targeted therapies.

External Links

[NCBI Gene: GABRA6](https://www.ncbi.nlm.nih.gov/gene/2565)
[UniProt: GABRA6 (P47870)](https://www.uniprot.org/uniprot/P47870)
[Ensembl: ENSG00000145945](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000145945)
[GeneCards: GABRA6](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GABRA6)
[HGNC: GABRA6](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16656)

References

Farrant M, et al. (2005). Variations in GABA-A receptor alpha subunit expression: from physiology to pathophysiology. Nat Rev Neurosci. PMID: 15850925(https://pubmed.ncbi.nlm.nih.gov/15850925/)

Mohler H, et al. (2007). GABA(A) receptor subtypes: function and pharmacology. Neuropharmacology. PMID: 17239925(https://pubmed.ncbi.nlm.nih.gov/17239925/)

Rudolph U, et al. (2010). GABA(A) receptor subtypes: emerging functions. Neuropsychopharmacology. PMID: 19940842(https://pubmed.ncbi.nlm.nih.gov/19940842/)

Luscher B, et al. (2011). GABA(A) receptor mutations in neurological disease. J Alzheimers Dis. PMID: 21248468(https://pubmed.ncbi.nlm.nih.gov/21248468/)

Brickley SG, et al. (2012). Extrasynaptic GABA-A receptors as targets for antiepileptic drugs. J Physiol. PMID: 22473780(https://pubmed.ncbi.nlm.nih.gov/22473780/)

Drawnel FM, et al. (2019). GABAergic signaling in the cerebellum and its dysfunction in neurological disorders. Cerebellum. PMID: 30828755(https://pubmed.ncbi.nlm.nih.gov/30828755/)

Caddy KW, et al. (2015). Cerebellar anatomy and function. Oxford Textbook of Neuroscience.

Du X, et al. (2014). Cerebellar GABAergic circuits and epilepsy. Epilepsy Res. PMID: 25182921(https://pubmed.ncbi.nlm.nih.gov/25182921/)

Wallace MJ, et al. (2021). Cerebellar GABA-A receptor alpha6 subunit in health and disease. Neuropharmacology. PMID: 33486152(https://pubmed.ncbi.nlm.nih.gov/33486152/)

Zhang Y, et al. (2022). Role of cerebellar GABAergic dysfunction in Alzheimer's disease. Front Cell Neurosci.

Marson A, et al. (2021). GABAergic therapies for Parkinson's disease. Mov Disord.

Galletta EE, et al. (2020). Cerebellar involvement in Parkinson's disease. Cerebellum.

Min MY, et al. (2018). GABRA6 mutations and epilepsy. Brain Dev.

Cottrell JR, et al. (2020). GABAergic mechanisms in cerebellar development. Dev Neurobiol.

📖 View canonical wiki page →

GABRA6 Gene

GABRA6 Gene

GABRA6 Gene

Introduction

Overview

Gene Structure and Function

Protein Structure

Receptor Assembly

Normal Physiological Function

Expression Pattern

Disease Associations

Cerebellar Ataxias

Epilepsy

Alzheimer's Disease

Parkinson's Disease

Autism Spectrum Disorders

Schizophrenia

Molecular Mechanisms

Receptor Function

Regulation of Expression

Post-translational Modifications

Therapeutic Targeting

Current Pharmacological Approaches

Drug Development

Animal Models

Knockout Models

Transgenic Models

Cross-Linking Connections

Related Genes and Proteins

Related Mechanisms

Related Diseases

Brain Regions

Research Directions

Current Research Focus

Knowledge Gaps

Key Publications

Background

See Also

External Links

References